Company research / PLX
Protalix BioTherapeutics, Inc. (PLX)
- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
For the year ended 2025-12-31, Protalix BioTherapeutics, Inc. reported revenue of $52.74M. Revenue fell 1.2% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $80.62M.
Key ratios (year ended 2025-12-31)
48.8%
Gross margin (computed)
-10.4%
Operating margin
-12.5%
Net margin
-13.7%
Return on year-end equity
-1.2%
Revenue growth (YoY)
Beyond the statements
Follow the company.
Explore new filings, reported insider transactions and company relationships.